1
|
Papke RL, Quadri M, Gulsevin A. Silent agonists for α7 nicotinic acetylcholine receptors. Pharmacol Res 2023; 190:106736. [PMID: 36940890 DOI: 10.1016/j.phrs.2023.106736] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/10/2022] [Revised: 03/07/2023] [Accepted: 03/14/2023] [Indexed: 03/23/2023]
Abstract
We discuss models for the activation and desensitization of α7 nicotinic acetylcholine receptors (nAChRs) and the effects of efficacious type II positive allosteric modulators (PAMs) that destabilize α7 desensitized states. Type II PAMs such as PNU-120596 can be used to distinguish inactive compounds from silent agonists, compounds that produce little or no channel activation but stabilize the non-conducting conformations associated with desensitization. We discuss the effects of α7 nAChRs in cells of the immune system and their roles in modulating inflammation and pain through what has come to be known as the cholinergic anti-inflammatory system (CAS). Cells controlling CAS do not generate ion channel currents but rather respond to α7 drugs by modulating intracellular signaling pathways analogous to the effects of metabotropic receptors. Metabotropic signaling by α7 receptors appears to be mediated by receptors in nonconducting conformations and can be accomplished by silent agonists. We discuss electrophysiological structure-activity relationships for α7 silent agonists and their use in cell-based and in vivo assays for CAS regulation. We discuss the strongly desensitizing partial agonist GTS-21 and its effectiveness in modulation of CAS. We also review the properties of the silent agonist NS6740, which is remarkably effective at maintaining α7 receptors in PAM-sensitive desensitized states. Most silent agonists bind to sites overlapping those for orthosteric agonists, but some appear to bind to allosteric sites. Finally, we discuss α9⁎ nAChRs and their potential role in CAS, and ligands that will be useful in defining and distinguishing the specific roles of α7 and α9 in CAS.
Collapse
Affiliation(s)
- Roger L Papke
- Department of Pharmacology and Therapeutics, University of Florida, PO Box 100267 Gainesville, FL 32610 USA (RLP); Olon S.p.A., Strada Rivoltana, Km 6/7 - 20053 Rodano (MI) - ITALY (MQ); Department of Chemistry, Center for Structural Biology, Vanderbilt University, Nashville, Tennessee, USA, 37212 (AG).
| | - Marta Quadri
- Department of Pharmacology and Therapeutics, University of Florida, PO Box 100267 Gainesville, FL 32610 USA (RLP); Olon S.p.A., Strada Rivoltana, Km 6/7 - 20053 Rodano (MI) - ITALY (MQ); Department of Chemistry, Center for Structural Biology, Vanderbilt University, Nashville, Tennessee, USA, 37212 (AG)
| | - Alican Gulsevin
- Department of Pharmacology and Therapeutics, University of Florida, PO Box 100267 Gainesville, FL 32610 USA (RLP); Olon S.p.A., Strada Rivoltana, Km 6/7 - 20053 Rodano (MI) - ITALY (MQ); Department of Chemistry, Center for Structural Biology, Vanderbilt University, Nashville, Tennessee, USA, 37212 (AG)
| |
Collapse
|
2
|
Quadri M, Bonetti LR, Panini R, Tiso N, Morasso M, Lotti R, Marconi A, Pincelli C, Palazzo E. 438 CD271 modulates cutaneous squamous cell carcinoma growth and invasion in patient-derived spheroids and zebrafish avatar. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.09.452] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
3
|
Quadri M, Bonetti LR, Vaschieri C, Lotti R, Campanini L, Canossa M, Morasso M, Pincelli C, Marconi A, Palazzo E. 186 Dissecting the role of the common neurotrophin receptor CD271 in the skin: generation and characterization of a novel mouse model with keratinocyte-specific conditional deletion. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.09.197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
4
|
Papke RL, Andleeb H, Stokes C, Quadri M, Horenstein NA. Selective Agonists and Antagonists of α9 Versus α7 Nicotinic Acetylcholine Receptors. ACS Chem Neurosci 2022; 13:624-637. [PMID: 35167270 PMCID: PMC9547379 DOI: 10.1021/acschemneuro.1c00747] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Nicotinic acetylcholine receptors containing α9 subunits are essential for the auditory function and have been implicated, along with α7-containing nicotinic receptors, as potential targets for the treatment of inflammatory and neuropathic pain. The study of α9-containing receptors has been hampered by the lack of selective agonists. The only α9-selective antagonists previously identified are peptide conotoxins. Curiously, the activity of α7 and α9 receptors as modulators of inflammatory pain appears to not rely strictly on ion channel activation, which led to the identification of α7 "silent agonists" and phosphocholine as an "unconventional agonist" for α9 containing receptors. The parallel testing of the α7 silent agonist p-CF3-diEPP and phosphocholine led to the discovery that p-CF3-diEPP was an α9 agonist. In this report, we compared the activity of α7 and α9 with a family of structurally related compounds, most of which were previously shown to be α7 partial or silent agonists. We identify several potent α9-selective agonists as well as numerous potent and selective α9 antagonists and describe the structural basis for these activities. Several of these compounds have previously been shown to be effective in animal models of inflammatory pain, an activity that was assumed to be due to α7 silent agonism but may, in fact, be due to α9 activity. The α9-selective conotoxin antagonists have also been shown to reduce pain in similar models. Our identification of these new α9 agonists and antagonists may prove to be invaluable for defining an optimal approach for treating pain, allowing for reduced use of opioid drugs.
Collapse
Affiliation(s)
- Roger L. Papke
- Department of Pharmacology and Therapeutics, University of Florida, PO Box 100267 Gainesville, FL 32610 USA (CS, RLP),To whom correspondence should be addressed: Roger L. Papke, Ph.D., , Department of Pharmacology and Therapeutics, University of Florida, PO Box 100267, Gainesville FL, 32610-0267
| | - Hina Andleeb
- Department of Chemistry, University of Florida, PO Box 117200, Gainesville, FL 32611-7200 USA (HA, MQ, NAH)
| | - Clare Stokes
- Department of Pharmacology and Therapeutics, University of Florida, PO Box 100267 Gainesville, FL 32610 USA (CS, RLP)
| | - Marta Quadri
- Department of Chemistry, University of Florida, PO Box 117200, Gainesville, FL 32611-7200 USA (HA, MQ, NAH)
| | - Nicole A. Horenstein
- Department of Chemistry, University of Florida, PO Box 117200, Gainesville, FL 32611-7200 USA (HA, MQ, NAH)
| |
Collapse
|
5
|
Quadri M, Baudouin C, Lotti R, Palazzo E, Campanini L, Bernard F, Bellemère G, Pincelli C, Marconi A. 331 Characterisation of interfollicular stem cells and early TA cells during the transition from infant to child skin. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.08.339] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
6
|
Saettini F, Castelli I, Provenzi M, Fazio G, Quadri M, Cazzaniga G, Sala S, Dell'Acqua F, Sieni E, Coniglio ML, Pezzoli L, Iascone M, Vendemini F, Balduzzi AC, Biondi A, Rizzari C, Bonanomi S. A novel homozygous disruptive PRF1 variant (K285Sfs*4) causes very early-onset of familial hemophagocytic lymphohystiocytosis type 2. Pediatr Hematol Oncol 2021; 38:174-178. [PMID: 32696691 DOI: 10.1080/08880018.2020.1793849] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- F Saettini
- Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation, Monza, Italy
| | - I Castelli
- Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation, Monza, Italy
| | - M Provenzi
- Pediatric Unit, Hospital Papa Giovanni XXIII, Bergamo, Italy
| | - G Fazio
- Centro Ricerca Tettamanti, University of Milan Bicocca, Monza, Italy
| | - M Quadri
- Centro Ricerca Tettamanti, University of Milan Bicocca, Monza, Italy
| | - G Cazzaniga
- Centro Ricerca Tettamanti, University of Milan Bicocca, Monza, Italy.,Department of Medicine and Surgery, University of Milan Bicocca, Monza, Italy
| | - S Sala
- Centro Ricerca Tettamanti, University of Milan Bicocca, Monza, Italy
| | - F Dell'Acqua
- Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation, Monza, Italy
| | - E Sieni
- Department of Paediatric Oncohematology, Meyer Children's University Hospital, Florence, Italy
| | - M L Coniglio
- Department of Paediatric Oncohematology, Meyer Children's University Hospital, Florence, Italy
| | - L Pezzoli
- Molecular Genetics Laboratory, USSD LGM, Papa Giovanni XXIII Hospital, Bergamo, Italy
| | - M Iascone
- Molecular Genetics Laboratory, USSD LGM, Papa Giovanni XXIII Hospital, Bergamo, Italy
| | - F Vendemini
- Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation, Monza, Italy
| | - A C Balduzzi
- Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation, Monza, Italy
| | - A Biondi
- Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation, Monza, Italy.,Centro Ricerca Tettamanti, University of Milan Bicocca, Monza, Italy
| | - C Rizzari
- Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation, Monza, Italy
| | - S Bonanomi
- Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation, Monza, Italy
| |
Collapse
|
7
|
Pismataro MC, Horenstein NA, Stokes C, Quadri M, De Amici M, Papke RL, Dallanoce C. Design, synthesis, and electrophysiological evaluation of NS6740 derivatives: Exploration of the structure-activity relationship for alpha7 nicotinic acetylcholine receptor silent activation. Eur J Med Chem 2020; 205:112669. [PMID: 32810771 DOI: 10.1016/j.ejmech.2020.112669] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2020] [Revised: 07/13/2020] [Accepted: 07/14/2020] [Indexed: 11/15/2022]
Abstract
The α7 nicotinic acetylcholine receptor (nAChR) silent agonists, able to induce receptor desensitization and promote the α7 metabotropic function, are emerging as new promising therapeutic anti-inflammatory agents. Herein, we report the structure-activity relationship investigation of the archetypal silent agonist NS6740 (1,4-diazabicyclo[3.2.2]nonan-4-yl(5-(3-(trifluoromethyl)-phenyl)-furan-2-yl)methanone) (1) to elucidate the ligand-receptor interactions responsible for the α7 silent activation. In this study, NS6740 fragments 11-16 and analogs 17-32 were designed, synthesized, and assayed on human α7 nAChRs expressed in Xenopus laevis oocytes with two-electrode voltage clamping experiments. All together the structural portions of NS6740 were critical to engender its peculiar activity profile. The diazabicyclic nucleus was essential but not sufficient for inducing α7 silent activation. The central hydrogen-bond acceptor core and the aromatic moiety were crucial for promoting prolonged α7 receptor binding and sustained desensitization. Compounds 13 and 17 were efficacious partial agonists. Compounds 12, 21, 23-26, and 30 strongly desensitized α7 nAChR and therefore may be of interest for additional investigation of inflammation responses. We gained key structural information useful for further silent agonist development.
Collapse
Affiliation(s)
- Maria Chiara Pismataro
- Department of Pharmaceutical Sciences, Medicinal Chemistry Section "Pietro Pratesi", University of Milan, Via L. Mangiagalli 25, 20133, Milan, Italy; Department of Chemistry, University of Florida, P.O. Box 117200, Gainesville, FL 32611-7200, USA; Department of Pharmacology and Therapeutics, University of Florida, P.O. Box 100267, Gainesville, FL 32610-0267, USA
| | - Nicole A Horenstein
- Department of Chemistry, University of Florida, P.O. Box 117200, Gainesville, FL 32611-7200, USA
| | - Clare Stokes
- Department of Pharmacology and Therapeutics, University of Florida, P.O. Box 100267, Gainesville, FL 32610-0267, USA
| | - Marta Quadri
- Department of Pharmaceutical Sciences, Medicinal Chemistry Section "Pietro Pratesi", University of Milan, Via L. Mangiagalli 25, 20133, Milan, Italy; Department of Chemistry, University of Florida, P.O. Box 117200, Gainesville, FL 32611-7200, USA; Department of Pharmacology and Therapeutics, University of Florida, P.O. Box 100267, Gainesville, FL 32610-0267, USA
| | - Marco De Amici
- Department of Pharmaceutical Sciences, Medicinal Chemistry Section "Pietro Pratesi", University of Milan, Via L. Mangiagalli 25, 20133, Milan, Italy
| | - Roger L Papke
- Department of Pharmacology and Therapeutics, University of Florida, P.O. Box 100267, Gainesville, FL 32610-0267, USA
| | - Clelia Dallanoce
- Department of Pharmaceutical Sciences, Medicinal Chemistry Section "Pietro Pratesi", University of Milan, Via L. Mangiagalli 25, 20133, Milan, Italy.
| |
Collapse
|
8
|
Saettini F, Fazio G, Corti P, Quadri M, Bugarin C, Gaipa G, Penco F, Moratto D, Chiarini M, Baronio M, Gazzurelli L, Imberti L, Paghera S, Giliani S, Cazzaniga G, Plebani A, Badolato R, Lougaris V, Gattorno M, Biondi A. Two siblings presenting with novel ADA2 variants, lymphoproliferation, persistence of large granular lymphocytes, and T-cell perturbations. Clin Immunol 2020; 218:108525. [PMID: 32659374 DOI: 10.1016/j.clim.2020.108525] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2020] [Revised: 06/26/2020] [Accepted: 07/07/2020] [Indexed: 12/25/2022]
Abstract
The presence of large granular lymphocytes has been reported in patients with ADA2 deficiency and T-LGL leukemia. Here we describe two siblings with novel ADA2 variants, expanding the mutational spectrum of ADA2 deficiency. We show that lymphoproliferation, persistence of large granular lymphocytes, T-cell perturbations, and activation of PI3K pathway, measured by means of phosphorylation levels of S6, are detectable in DADA2 patients without T-LGL leukemia.
Collapse
Affiliation(s)
- F Saettini
- Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation, Monza, Italy.
| | - G Fazio
- Centro Ricerca Tettamanti, University of Milan Bicocca, Monza, Italy
| | - P Corti
- Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation, Monza, Italy
| | - M Quadri
- Centro Ricerca Tettamanti, University of Milan Bicocca, Monza, Italy
| | - C Bugarin
- Centro Ricerca Tettamanti, University of Milan Bicocca, Monza, Italy
| | - G Gaipa
- Centro Ricerca Tettamanti, University of Milan Bicocca, Monza, Italy
| | - F Penco
- Center for Autoinflammatory disease and Immunodeficiencies, IRCCS G. Gaslini, Genova, Italy
| | - D Moratto
- Flow cytometry Laboratory, Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy
| | - M Chiarini
- Flow cytometry Laboratory, Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy
| | - M Baronio
- Pediatrics Clinic and Institute of Molecular Medicine A. Novicelli, Department of Clinical and Experimental Sciences, University of Brescia, ASST-Spedali Civili of Brescia, Brescia, Italy
| | - L Gazzurelli
- Pediatrics Clinic and Institute of Molecular Medicine A. Novicelli, Department of Clinical and Experimental Sciences, University of Brescia, ASST-Spedali Civili of Brescia, Brescia, Italy
| | - L Imberti
- Centro di Ricerca Emato-oncologica AIL (CREA), ASST Spedali Civili, Brescia, Italy
| | - S Paghera
- Centro di Ricerca Emato-oncologica AIL (CREA), ASST Spedali Civili, Brescia, Italy
| | - S Giliani
- Pediatrics Clinic and Institute of Molecular Medicine A. Novicelli, Department of Clinical and Experimental Sciences, University of Brescia, ASST-Spedali Civili of Brescia, Brescia, Italy
| | - G Cazzaniga
- Centro Ricerca Tettamanti, University of Milan Bicocca, Monza, Italy; Department of Medicine and Surgery, University of Milan Bicocca, Monza, Italy
| | - A Plebani
- Pediatrics Clinic and Institute of Molecular Medicine A. Novicelli, Department of Clinical and Experimental Sciences, University of Brescia, ASST-Spedali Civili of Brescia, Brescia, Italy
| | - R Badolato
- Pediatrics Clinic and Institute of Molecular Medicine A. Novicelli, Department of Clinical and Experimental Sciences, University of Brescia, ASST-Spedali Civili of Brescia, Brescia, Italy
| | - V Lougaris
- Pediatrics Clinic and Institute of Molecular Medicine A. Novicelli, Department of Clinical and Experimental Sciences, University of Brescia, ASST-Spedali Civili of Brescia, Brescia, Italy
| | - M Gattorno
- Center for Autoinflammatory disease and Immunodeficiencies, IRCCS G. Gaslini, Genova, Italy
| | - A Biondi
- Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation, Monza, Italy; Centro Ricerca Tettamanti, University of Milan Bicocca, Monza, Italy
| |
Collapse
|
9
|
Godin JR, Roy P, Quadri M, Bagdas D, Toma W, Narendrula-Kotha R, Kishta OA, Damaj MI, Horenstein NA, Papke RL, Simard AR. A silent agonist of α7 nicotinic acetylcholine receptors modulates inflammation ex vivo and attenuates EAE. Brain Behav Immun 2020; 87:286-300. [PMID: 31874200 PMCID: PMC7604877 DOI: 10.1016/j.bbi.2019.12.014] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/21/2019] [Revised: 12/20/2019] [Accepted: 12/20/2019] [Indexed: 12/20/2022] Open
Abstract
Nicotinic acetylcholine receptors (nAChRs) are best known to function as ligand-gated ion channels in the nervous system. However, recent evidence suggests that nicotine modulates inflammation by desensitizing non-neuronal nAChRs, rather than by inducing channel opening. Silent agonists are molecules that selectively induce the desensitized state of nAChRs while producing little or no channel opening. A silent agonist of α7 nAChRs has recently been shown to reduce inflammation in an animal model of inflammatory pain. The objective of this study was to determine whether a silent agonist of α7 nAChRs can also effectively modulate inflammation and disease manifestation in an animal model of multiple sclerosis. We first evaluated the effects of various nAChR ligands and of an α7 nAChR-selective silent agonist, 1-ethyl-4-(3-(bromo)phenyl)piperazine (m-bromo PEP), on the modulation of mouse bone marrow-derived monocyte/macrophage (BMDM) numbers, phenotype and cytokine production. The non-competitive antagonist mecamylamine and the silent agonist m-bromo PEP reduced pro-inflammatory BMDM numbers by affecting their viability and proliferation. Both molecules also significantly reduced cytokine production by mouse BMDMs and significantly ameliorated disease in experimental autoimmune encephalomyelitis. Finally, m-bromo PEP also reduced chronic inflammatory pain in mice. Taken together, our results further support the hypothesis that nAChRs may modulate inflammation via receptor desensitization rather than channel opening. α7 nAChR-selective silent agonists may thus be a novel source of anti-inflammatory compounds that could be used for the treatment of inflammatory disorders.
Collapse
Affiliation(s)
- Jean-Rémi Godin
- Département de Chimie et Biochimie, Université de Moncton, Moncton, NB, Canada
| | - Patrick Roy
- Département de Chimie et Biochimie, Université de Moncton, Moncton, NB, Canada
| | - Marta Quadri
- Department of Pharmacology and Therapeutics, University of Florida, PO Box 100267, Gainesville, FL, USA,Department of Chemistry, University of Florida, PO Box 117200, Gainesville, FL, USA
| | - Deniz Bagdas
- Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA, USA
| | - Wisam Toma
- Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA, USA
| | | | | | - M. Imad Damaj
- Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA, USA
| | - Nicole A. Horenstein
- Department of Pharmacology and Therapeutics, University of Florida, PO Box 100267, Gainesville, FL, USA
| | - Roger L. Papke
- Department of Chemistry, University of Florida, PO Box 117200, Gainesville, FL, USA
| | - Alain R. Simard
- Département de Chimie et Biochimie, Université de Moncton, Moncton, NB, Canada,Northern Ontario School of Medicine, Sudbury, ON, Canada,Department of Chemistry and Biochemistry, Laurentian University, Sudbury, ON, Canada,Department of Biology, Laurentian University, Sudbury, ON, Canada,Corresponding author at: Northern Ontario School of Medicine, 935 Ramsey Lake Rd., Sudbury, ON P3E 2C6, Canada. (A.R. Simard)
| |
Collapse
|
10
|
Horenstein NA, Quadri M, Stokes C, Shoaib M, Papke RL. Cracking the Betel Nut: Cholinergic Activity of Areca Alkaloids and Related Compounds. Nicotine Tob Res 2020; 21:805-812. [PMID: 29059390 DOI: 10.1093/ntr/ntx187] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2017] [Accepted: 09/14/2017] [Indexed: 12/12/2022]
Abstract
INTRODUCTION The use of betel quid is the most understudied major addiction in the world. The neuropsychological activity of betel quid has been attributed to alkaloids of Areca catechu. With the goal of developing novel addiction treatments, we evaluate the muscarinic and nicotinic activity of the four major Areca alkaloids: arecoline, arecaidine, guvacoline, and guvacine and four structurally related compounds. METHODS Acetylcholine receptors were expressed in Xenopus oocytes and studied with two-electrode voltage clamp. RESULTS Both arecoline- and guvacoline-activated muscarinic acetylcholine receptors (mAChR), while only arecoline produced significant activation of nicotinic AChR (nAChR). We characterized four additional arecoline-related compounds, seeking an analog that would retain selective activity for a α4* nAChR, with diminished effects on mAChR and not be a desensitizer of α7 nAChR. We show that this profile is largely met by isoarecolone. Three additional arecoline analogs were characterized. While the quaternary dimethyl analog had a broad range of activities, including activation of mAChR and muscle-type nAChR, the methyl analog only activated a range of α4* nAChR, albeit with low potency. The ethyl analog had no detectable cholinergic activity. CONCLUSIONS Evidence indicates that α4* nAChR are at the root of nicotine addiction, and this may also be the case for betel addiction. Our characterization of isoarecolone and 1-(4-methylpiperazin-1-yl) ethanone as truly selective α4*nAChR selective partial agonists with low muscarinic activity may point toward a promising new direction for the development of drugs to treat both nicotine and betel addiction. IMPLICATIONS Nearly 600 million people use Areca nut, often with tobacco. Two of the Areca alkaloids are muscarinic acetylcholine receptor agonists, and one, arecoline, is a partial agonist for the α4* nicotinic acetylcholine receptors (nAChR) associated with tobacco addiction. The profile of arecoline activity suggested its potential to be used as a scaffold for developing new tobacco cessation drugs if analogs can be identified that retain the same nicotinic receptor selectivity without muscarinic activity. We report that isoarecolone is a selective partial agonist for α4* nAChR with minimal muscarinic activity and 1-(4-methylpiperazin-1-yl) ethanone has similar nAChR selectivity and no detectable muscarinic action.
Collapse
Affiliation(s)
| | - Marta Quadri
- Department of Chemistry, University of Florida, Gainesville, FL.,Department of Pharmacology and Therapeutics, University of Florida, Gainesville, FL
| | - Clare Stokes
- Department of Pharmacology and Therapeutics, University of Florida, Gainesville, FL
| | - Mohammed Shoaib
- Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK
| | - Roger L Papke
- Department of Pharmacology and Therapeutics, University of Florida, Gainesville, FL
| |
Collapse
|
11
|
Gulsevin A, Papke RL, Stokes C, Garai S, Thakur GA, Quadri M, Horenstein NA. Allosteric Agonism of α7 Nicotinic Acetylcholine Receptors: Receptor Modulation Outside the Orthosteric Site. Mol Pharmacol 2019; 95:606-614. [PMID: 30944209 DOI: 10.1124/mol.119.115758] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2019] [Accepted: 03/24/2019] [Indexed: 12/15/2022] Open
Abstract
Nicotinic acetylcholine receptors (nAChRs) are members of the Cys-loop superfamily of ligand-gated ion channels. Typically, channel activation follows the binding of agonists to the orthosteric binding sites of the receptor. α7 nAChRs have a very low probability of channel activation, which can be reversed by the binding of α7 selective positive allosteric modulators (PAMs) to putative sites within the transmembrane domains. Although typical PAMs, like PNU-120596, require coapplication of an orthosteric agonist to produce large channel activations, some, like GAT107 and B-973B [(S)-3-(3,4-difluorophenyl)-N-(1-(6-(4-(pyridin-2-yl)piperazin-1-yl)pyrazin-2-yl)ethyl)propanamide], are characterized as allosteric activating PAMs, which also bind to an allosteric activation (AA) site in the extracellular domain and activate the α7 ion channel by themselves. We had previously characterized N,N-diethyl-N'-phenylpiperazine analogs with various functions. In this work, we docked members of this family to a homology model of the α7 receptor extracellular domain. The compound 1,1-diethyl-4(naphthalene-2-yl)piperazin-1-ium (2NDEP) a weak partial agonist, showed particularly favorable docking and binding energies at the putative AA site of the receptor. We hypothesized that 2NDEP could couple with PAMs through the AA site. This hypothesis was tested with the α7 mutant C190A, which is not activated by orthosteric agonists but is effectively activated by GAT107. The results showed that 2NDEP acts as an allosteric agonist of α7C190A when coapplied with the PAM PNU-120596. Also, the allosteric activity was nearly abolished upon coapplication with the AA site-selective antagonist 2,3,5,6MP-TQS (cis-trans-4-(2,3,5,6-tetramethylphenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide), consistent with AA site involvement. Overall, our findings show a novel mode of agonism through an allosteric site in the extracellular domain of α7 nAChR.
Collapse
Affiliation(s)
- Alican Gulsevin
- Departments of Chemistry (A.G., M.Q., N.A.H.) and Pharmacology and Therapeutics (R.L.P, C.S., M.Q.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts (S.G., G.A.T.)
| | - Roger L Papke
- Departments of Chemistry (A.G., M.Q., N.A.H.) and Pharmacology and Therapeutics (R.L.P, C.S., M.Q.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts (S.G., G.A.T.)
| | - Clare Stokes
- Departments of Chemistry (A.G., M.Q., N.A.H.) and Pharmacology and Therapeutics (R.L.P, C.S., M.Q.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts (S.G., G.A.T.)
| | - Sumanta Garai
- Departments of Chemistry (A.G., M.Q., N.A.H.) and Pharmacology and Therapeutics (R.L.P, C.S., M.Q.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts (S.G., G.A.T.)
| | - Ganesh A Thakur
- Departments of Chemistry (A.G., M.Q., N.A.H.) and Pharmacology and Therapeutics (R.L.P, C.S., M.Q.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts (S.G., G.A.T.)
| | - Marta Quadri
- Departments of Chemistry (A.G., M.Q., N.A.H.) and Pharmacology and Therapeutics (R.L.P, C.S., M.Q.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts (S.G., G.A.T.)
| | - Nicole A Horenstein
- Departments of Chemistry (A.G., M.Q., N.A.H.) and Pharmacology and Therapeutics (R.L.P, C.S., M.Q.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts (S.G., G.A.T.)
| |
Collapse
|
12
|
Simard A, Richter K, Roy D, Espinosa ES, Roy P, Godin J, Grau V, Quadri M, Horenstein N, Papke R. Nicotinic acetylcholine receptor silent agonists modulate inflammation. FASEB J 2019. [DOI: 10.1096/fasebj.2019.33.1_supplement.lb236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Alain Simard
- Medical Sciences DivisionNorthern Ontario School of MedicineSudburyONCanada
- Department of Chemistry and BiochemistryLaurentian UniversitySudburyONCanada
- Department of BiologyLaurentian UniversitySudburyONCanada
- Départment de Chimie et BiochimieUniversité de MonctonMonctonNBCanada
| | - Katrin Richter
- Department of General and Thoracic SurgeryJustus‐Liebig UniversityGiessenGermany
| | - Danika Roy
- Department of Chemistry and BiochemistryLaurentian UniversitySudburyONCanada
| | | | - Patrick Roy
- Départment de Chimie et BiochimieUniversité de MonctonMonctonNBCanada
| | - Jean‐Rémi Godin
- Départment de Chimie et BiochimieUniversité de MonctonMonctonNBCanada
| | - Veronika Grau
- Department of General and Thoracic SurgeryJustus‐Liebig UniversityGiessenGermany
| | - Marta Quadri
- Department of ChemistryUniversity of FloridaGainesvilleFL
- Department of Pharmacology and TherapeuticsUniversity of FloridaGainesvilleFL
| | | | - Roger Papke
- Department of Pharmacology and TherapeuticsUniversity of FloridaGainesvilleFL
| |
Collapse
|
13
|
Murray AB, Quadri M, Li H, McKenna R, Horenstein NA. Synthesis of saccharin-glycoconjugates targeting carbonic anhydrase using a one-pot cyclization/deprotection strategy. Carbohydr Res 2019; 476:65-70. [PMID: 30921738 DOI: 10.1016/j.carres.2019.03.001] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2018] [Revised: 02/23/2019] [Accepted: 03/02/2019] [Indexed: 11/26/2022]
Abstract
Carbonic anhydrase IX (CA IX) has been identified as a biomarker and drug target for several malignant tumors due to its role in cancer cell growth and proliferation. Simple cyclic sulfonamides, like saccharin (SAC), have shown up to a 60-fold selectivity towards CA IX over other ubiquitous CA isoforms, with greater selectivity obtained applying the "tail-approach" to derivatize SAC with a methylene triazole linker that connected to a "tail" beta glucoside. These modifications of SAC led to an increased selectivity of more than 1000-fold towards CA IX, whereas clinically available CA inhibitors show little to no isoform selectivity. As part of our interest in the development of new CA inhibitors, we found the existing synthetic protocol, which relies on a N-tert-butyl saccharin intermediate, to be problematic in the final deprotection steps. We therefore describe an alternative approach to the synthesis of these compounds featuring a gentle "one pot" deprotection/cyclization as the final synthetic step, and report new galactosyl and glucosyl conjugates with low to mid nM inhibition of CA IX.
Collapse
Affiliation(s)
- Akilah B Murray
- Department of Biochemistry and Molecular Biology, College of Medicine, University of Florida, Gainesville, FL, 32610, USA
| | - Marta Quadri
- Department of Chemistry, College of Liberal Arts and Sciences, University of Florida, Gainesville, FL, 32611, USA
| | - Haoxi Li
- Department of Chemistry, College of Liberal Arts and Sciences, University of Florida, Gainesville, FL, 32611, USA
| | - Robert McKenna
- Department of Biochemistry and Molecular Biology, College of Medicine, University of Florida, Gainesville, FL, 32610, USA
| | - Nicole A Horenstein
- Department of Chemistry, College of Liberal Arts and Sciences, University of Florida, Gainesville, FL, 32611, USA.
| |
Collapse
|
14
|
Quadri M, Garai S, Thakur GA, Stokes C, Gulsevin A, Horenstein NA, Papke RL. Macroscopic and Microscopic Activation of α7 Nicotinic Acetylcholine Receptors by the Structurally Unrelated Allosteric Agonist-Positive Allosteric Modulators (ago-PAMs) B-973B and GAT107. Mol Pharmacol 2019; 95:43-61. [PMID: 30348894 PMCID: PMC6277926 DOI: 10.1124/mol.118.113340] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2018] [Accepted: 10/18/2018] [Indexed: 01/25/2023] Open
Abstract
B-973 is an efficacious type II positive allosteric modulator (PAM) of α7 nicotinic acetylcholine receptors that, like 4BP-TQS and its active isomer GAT107, can produce direct allosteric activation in addition to potentiation of orthosteric agonist activity, which identifies it as an allosteric activating (ago)-PAM. We compared the properties of B-973B, the active enantiomer of B-973, with those of GAT107 regarding the separation of allosteric potentiation and activation. Both ago-PAMs can strongly activate mutants of α7 that are insensitive to standard orthosteric agonists like acetylcholine. Likewise, the activity of both ago-PAMs is largely eliminated by the M254L mutation in the putative transmembrane PAM-binding site. Allosteric activation by B-973B appeared more protracted than that produced by GAT107, and B-973B responses were relatively insensitive to the noncompetitive antagonist mecamylamine compared with GAT107 responses. Similar differences are also seen in the single-channel currents. The two agents generate unique profiles of full-conductance and subconductance states, with B-973B producing protracted bursts, even in the presence of mecamylamine. Modeling and docking studies suggest that the molecular basis for these effects depends on specific interactions in both the extracellular and transmembrane domains of the receptor.
Collapse
Affiliation(s)
- Marta Quadri
- Departments of Pharmacology and Therapeutics (M.Q., C.S., R.L.P.) and Chemistry (M.Q., A.G., N.A.H.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (S.G., G.A.T.)
| | - Sumanta Garai
- Departments of Pharmacology and Therapeutics (M.Q., C.S., R.L.P.) and Chemistry (M.Q., A.G., N.A.H.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (S.G., G.A.T.)
| | - Ganesh A Thakur
- Departments of Pharmacology and Therapeutics (M.Q., C.S., R.L.P.) and Chemistry (M.Q., A.G., N.A.H.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (S.G., G.A.T.)
| | - Clare Stokes
- Departments of Pharmacology and Therapeutics (M.Q., C.S., R.L.P.) and Chemistry (M.Q., A.G., N.A.H.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (S.G., G.A.T.)
| | - Alican Gulsevin
- Departments of Pharmacology and Therapeutics (M.Q., C.S., R.L.P.) and Chemistry (M.Q., A.G., N.A.H.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (S.G., G.A.T.)
| | - Nicole A Horenstein
- Departments of Pharmacology and Therapeutics (M.Q., C.S., R.L.P.) and Chemistry (M.Q., A.G., N.A.H.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (S.G., G.A.T.)
| | - Roger L Papke
- Departments of Pharmacology and Therapeutics (M.Q., C.S., R.L.P.) and Chemistry (M.Q., A.G., N.A.H.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (S.G., G.A.T.)
| |
Collapse
|
15
|
Quadri M, Bagdas D, Toma W, Stokes C, Horenstein NA, Damaj MI, Papke RL. The Antinociceptive and Anti-Inflammatory Properties of the α7 nAChR Weak Partial Agonist p-CF 3 N, N-diethyl- N'-phenylpiperazine. J Pharmacol Exp Ther 2018; 367:203-214. [PMID: 30111636 DOI: 10.1124/jpet.118.249904] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2018] [Accepted: 08/13/2018] [Indexed: 12/13/2022] Open
Abstract
Chronic pain and inflammatory diseases can be regulated by complex mechanisms involving α7 nicotinic acetylcholine receptors (nAChRs), making this subtype a promising drug target for anti-inflammatory therapies. Recent evidence suggests that suchtreatment of inflammatory pain may rely on metabotropic-like rather than ionotropic activation of the α7 receptor subtype in non-neuronal cells. We previously identified para-trifluoromethyl (p-CF3) N,N-diethyl-N'-phenylpiperazinium (diEPP) iodide to be among the compounds classified as silent agonists, which are very weak α7 partial agonists that are able to induce positive allosteric modulator (PAM)-sensitive desensitization. Such drugs have been shown to selectively promote α7 ionotropic-independent functions. Therefore, we here further investigated the electrophysiological profile of p-CF3 diEPP and its in vivo antinociceptive activity using Xenopus oocytes expressing α7, α4β2, or α3β4 nAChRs. The evoked currents confirmed p-CF3 diEPP to be α7-selective with a maximal agonism 5% that of acetylcholine (ACh). Coapplication of p-CF3 diEPP with the type II PAM 4-naphthalene-1-yl-3a,4,5,9b-tetrahydro-3-H-cyclopenta[c]quinoline-8-sulfonic acid amide (TQS) produced desensitization that could be converted to PAM-potentiated currents, which at a negative holding potential were up to 13-fold greater than ACh controls. Voltage-dependence experiments indicated that channel block may limit both control ACh and TQS-potentiated responses. Although no p-CF3 diEPP agonist activity was detected for the heteromeric nAChRs, it was a noncompetitive antagonist of these receptors. The compound displayed remarkable antihyperalgesic and antiedema effects in in vivo assays. The antinociceptive activity was dose and time dependent. The anti-inflammatory components were sensitive to the α7-selective antagonist methyllycaconitine, which supports the idea that these effects are mediated by the α7 nAChR.
Collapse
Affiliation(s)
- Marta Quadri
- Departments of Pharmacology and Therapeutics (M.Q., C.S., R.L.P.) and Chemistry (M.Q., N.A.H.), University of Florida, Gainesville, Florida; and Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia (D.B., W.T., M.I.D.)
| | - Deniz Bagdas
- Departments of Pharmacology and Therapeutics (M.Q., C.S., R.L.P.) and Chemistry (M.Q., N.A.H.), University of Florida, Gainesville, Florida; and Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia (D.B., W.T., M.I.D.)
| | - Wisam Toma
- Departments of Pharmacology and Therapeutics (M.Q., C.S., R.L.P.) and Chemistry (M.Q., N.A.H.), University of Florida, Gainesville, Florida; and Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia (D.B., W.T., M.I.D.)
| | - Clare Stokes
- Departments of Pharmacology and Therapeutics (M.Q., C.S., R.L.P.) and Chemistry (M.Q., N.A.H.), University of Florida, Gainesville, Florida; and Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia (D.B., W.T., M.I.D.)
| | - Nicole A Horenstein
- Departments of Pharmacology and Therapeutics (M.Q., C.S., R.L.P.) and Chemistry (M.Q., N.A.H.), University of Florida, Gainesville, Florida; and Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia (D.B., W.T., M.I.D.)
| | - M Imad Damaj
- Departments of Pharmacology and Therapeutics (M.Q., C.S., R.L.P.) and Chemistry (M.Q., N.A.H.), University of Florida, Gainesville, Florida; and Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia (D.B., W.T., M.I.D.)
| | - Roger L Papke
- Departments of Pharmacology and Therapeutics (M.Q., C.S., R.L.P.) and Chemistry (M.Q., N.A.H.), University of Florida, Gainesville, Florida; and Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia (D.B., W.T., M.I.D.)
| |
Collapse
|
16
|
Pincelli C, Quadri M, Lotti R, Palazzo E, Marconi A. 1088 Efficacy of AD-DER emollient in an in vitro atopic dermatitis model. J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.03.1101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
17
|
Marconi A, Quadri M, Lotti R, Palazzo E, Farnetani F, Pincelli C, Pellacani G. 1211 Bio-molecular profile of melanoma subtypes selected by reflectance confocal microscopy. J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.03.1226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
18
|
Lotti R, Atene C, Palazzo E, Quadri M, Marconi A, Zanocco-Marani T, Pincelli C. 049 Development of active mouse models to recapitulate pemphigus subtypes and to evaluate response to therapy. J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.03.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
19
|
Quadri M, Marconi A, Francesca T, Lotti R, Palazzo E, Farnetani F, Pincelli C, Pellacani G. 585 Aggressiveness of melanoma subtypes selected by reflectance confocal microscopy. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.07.782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
20
|
Quadri M, Stokes C, Gulsevin A, Felts ACJ, Abboud KA, Papke RL, Horenstein NA. Sulfonium as a Surrogate for Ammonium: A New α7 Nicotinic Acetylcholine Receptor Partial Agonist with Desensitizing Activity. J Med Chem 2017; 60:7928-7934. [PMID: 28885019 DOI: 10.1021/acs.jmedchem.7b00875] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Weak partial agonists that promote a desensitized state of the α7 nicotinic acetylcholine receptor (nAChR) have been associated with anti-inflammatory effects. Exemplar compounds feature a tertiary or quaternary ammonium group. We report the synthesis, structure, and electrophysiological evaluation of 1-ethyl-4-phenylthiomorpholin-1-ium triflate, a weak partial agonist with a sulfonium isostere of the ammonium pharmacophore. These results offer new insights in understanding nAChR-ligand interactions and provide a new chemical space to target the α7 nAChR.
Collapse
Affiliation(s)
- Marta Quadri
- Department of Chemistry, University of Florida , P.O. Box 117200, Gainesville, Florida 32611-7200, United States.,Department of Pharmacology and Therapeutics, University of Florida , P.O. Box 100267, Gainesville, Florida 32610, United States
| | - Clare Stokes
- Department of Pharmacology and Therapeutics, University of Florida , P.O. Box 100267, Gainesville, Florida 32610, United States
| | - Alican Gulsevin
- Department of Chemistry, University of Florida , P.O. Box 117200, Gainesville, Florida 32611-7200, United States
| | - Ashley C J Felts
- Department of Chemistry, Center of X-Ray Crystallography, University of Florida , P.O. Box 117200, Gainesville, Florida 32611-7200, United States
| | - Khalil A Abboud
- Department of Chemistry, Center of X-Ray Crystallography, University of Florida , P.O. Box 117200, Gainesville, Florida 32611-7200, United States
| | - Roger L Papke
- Department of Pharmacology and Therapeutics, University of Florida , P.O. Box 100267, Gainesville, Florida 32610, United States
| | - Nicole A Horenstein
- Department of Chemistry, University of Florida , P.O. Box 117200, Gainesville, Florida 32611-7200, United States
| |
Collapse
|
21
|
Quadri M, Matera C, Silnović A, Pismataro MC, Horenstein NA, Stokes C, Papke RL, Dallanoce C. Back Cover: Identification of α7 Nicotinic Acetylcholine Receptor Silent Agonists Based on the Spirocyclic Quinuclidine-Δ 2
-Isoxazoline Scaffold: Synthesis and Electrophysiological Evaluation (ChemMedChem 16/2017). ChemMedChem 2017. [DOI: 10.1002/cmdc.201700472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Marta Quadri
- Dipartimento di Scienze Farmaceutiche, Sezione di Chimica Farmaceutica “Pietro Pratesi”; Università degli Studi di Milano; Via Mangiagalli 25 20133 Milano Italy
- Department of Chemistry; University of Florida; P.O. Box 117200 Gainesville FL 32611-7200 USA
- Department of Pharmacology and Therapeutics; University of Florida; P.O. Box 100267 Gainesville FL 32610-0267 USA
| | - Carlo Matera
- Dipartimento di Scienze Farmaceutiche, Sezione di Chimica Farmaceutica “Pietro Pratesi”; Università degli Studi di Milano; Via Mangiagalli 25 20133 Milano Italy
- Institute for Bioengineering of Catalonia (IBEC); Parc Científic de Barcelona (PCB); Carrer Baldiri Reixac 15-21 08028 Barcelona Spain
| | - Almin Silnović
- Dipartimento di Scienze Farmaceutiche, Sezione di Chimica Farmaceutica “Pietro Pratesi”; Università degli Studi di Milano; Via Mangiagalli 25 20133 Milano Italy
| | - Maria Chiara Pismataro
- Dipartimento di Scienze Farmaceutiche, Sezione di Chimica Farmaceutica “Pietro Pratesi”; Università degli Studi di Milano; Via Mangiagalli 25 20133 Milano Italy
| | - Nicole A. Horenstein
- Department of Chemistry; University of Florida; P.O. Box 117200 Gainesville FL 32611-7200 USA
| | - Clare Stokes
- Department of Pharmacology and Therapeutics; University of Florida; P.O. Box 100267 Gainesville FL 32610-0267 USA
| | - Roger L. Papke
- Department of Pharmacology and Therapeutics; University of Florida; P.O. Box 100267 Gainesville FL 32610-0267 USA
| | - Clelia Dallanoce
- Dipartimento di Scienze Farmaceutiche, Sezione di Chimica Farmaceutica “Pietro Pratesi”; Università degli Studi di Milano; Via Mangiagalli 25 20133 Milano Italy
| |
Collapse
|
22
|
Quadri M, Matera C, Silnović A, Pismataro MC, Horenstein NA, Stokes C, Papke RL, Dallanoce C. Identification of α7 Nicotinic Acetylcholine Receptor Silent Agonists Based on the Spirocyclic Quinuclidine-Δ 2 -Isoxazoline Scaffold: Synthesis and Electrophysiological Evaluation. ChemMedChem 2017; 12:1335-1348. [PMID: 28494140 DOI: 10.1002/cmdc.201700162] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2017] [Revised: 05/10/2017] [Indexed: 12/29/2022]
Abstract
Compound 11 (3-(benzyloxy)-1'-methyl-1'-azonia-4H-1'-azaspiro[isoxazole-5,3'-bicyclo[2.2.2]octane] iodide) was selected from a previous set of nicotinic ligands as a suitable model compound for the design of new silent agonists of α7 nicotinic acetylcholine receptors (nAChRs). Silent agonists evoke little or no channel activation but can induce the α7 desensitized Ds state, which is sensitive to a type II positive allosteric modulator, such as PNU-120596. Introduction of meta substituents into the benzyloxy moiety of 11 led to two sets of tertiary amines and quaternary ammonium salts based on the spirocyclic quinuclidinyl-Δ2 -isoxazoline scaffold. Electrophysiological assays performed on Xenopus laevis oocytes expressing human α7 nAChRs highlighted four compounds that are endowed with a significant silent-agonism profile. Structure-activity relationships of this group of analogues provided evidence of the crucial role of the positive charge at the quaternary quinuclidine nitrogen atom. Moreover, the present study indicates that meta substituents, in particular halogens, on the benzyloxy substructure direct specific interactions that stabilize a desensitized conformational state of the receptor and induce silent activity.
Collapse
Affiliation(s)
- Marta Quadri
- Dipartimento di Scienze Farmaceutiche, Sezione di Chimica Farmaceutica "Pietro Pratesi", Università degli Studi di Milano, Via Mangiagalli 25, 20133, Milano, Italy.,Department of Chemistry, University of Florida, P.O. Box 117200, Gainesville, FL, 32611-7200, USA.,Department of Pharmacology and Therapeutics, University of Florida, P.O. Box 100267, Gainesville, FL, 32610-0267, USA
| | - Carlo Matera
- Dipartimento di Scienze Farmaceutiche, Sezione di Chimica Farmaceutica "Pietro Pratesi", Università degli Studi di Milano, Via Mangiagalli 25, 20133, Milano, Italy.,Institute for Bioengineering of Catalonia (IBEC), Parc Científic de Barcelona (PCB), Carrer Baldiri Reixac 15-21, 08028, Barcelona, Spain
| | - Almin Silnović
- Dipartimento di Scienze Farmaceutiche, Sezione di Chimica Farmaceutica "Pietro Pratesi", Università degli Studi di Milano, Via Mangiagalli 25, 20133, Milano, Italy
| | - Maria Chiara Pismataro
- Dipartimento di Scienze Farmaceutiche, Sezione di Chimica Farmaceutica "Pietro Pratesi", Università degli Studi di Milano, Via Mangiagalli 25, 20133, Milano, Italy
| | - Nicole A Horenstein
- Department of Chemistry, University of Florida, P.O. Box 117200, Gainesville, FL, 32611-7200, USA
| | - Clare Stokes
- Department of Pharmacology and Therapeutics, University of Florida, P.O. Box 100267, Gainesville, FL, 32610-0267, USA
| | - Roger L Papke
- Department of Pharmacology and Therapeutics, University of Florida, P.O. Box 100267, Gainesville, FL, 32610-0267, USA
| | - Clelia Dallanoce
- Dipartimento di Scienze Farmaceutiche, Sezione di Chimica Farmaceutica "Pietro Pratesi", Università degli Studi di Milano, Via Mangiagalli 25, 20133, Milano, Italy
| |
Collapse
|
23
|
Quadri M, Saltari A, Truzzi F, Lotti R, Palazzo E, Tiso N, Marconi A, Pincelli C. 457 The lack of CD271 favors melanoma metastasis in zebrafish and is associated with a reduced cell-cell adhesion. J Invest Dermatol 2016. [DOI: 10.1016/j.jid.2016.06.479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
24
|
Marconi A, Truzzi F, Saltari A, Lotti R, Palazzo E, Quadri M, Schafer P, Pincelli C. 142 CD271 regulates human keratinocyte functions through Phosphodiesterase 4 binding. J Invest Dermatol 2016. [DOI: 10.1016/j.jid.2016.06.160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
25
|
Quadri M, Papke RL, Horenstein NA. Dissection of N,N-diethyl-N'-phenylpiperazines as α7 nicotinic receptor silent agonists. Bioorg Med Chem 2015; 24:286-93. [PMID: 26707847 DOI: 10.1016/j.bmc.2015.12.017] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2015] [Revised: 11/30/2015] [Accepted: 12/08/2015] [Indexed: 12/13/2022]
Abstract
The α7 nicotinic acetylcholine receptor (nAChR) is a target for control of inflammation-related phenomena via compounds that are able to selectively induce desensitized states of the receptor. Compounds that selectively desensitize, without facilitating significant channel activation, are termed 'silent agonists' because they can be discriminated from antagonists by the currents evoked with co-application with type II positive allosteric modulators (PAMs). One example is N,N-diethyl-N'-phenyl-piperazine (diEPP) (J. Pharm. Exp. Ther.2014, 350, 665). We used Ullmann-type aryl amination to synthesize a panel of 27 compounds related to diEPP by substitutions at the aryl ring and in the linkage between the piperazine and phenyl rings. Two-electrode voltage clamping of the human α7 nAChR expressed in Xenopus oocytes revealed that it was possible to tune the behavior of compounds to show enhanced desensitization without corresponding partial agonist activity such that trifluoromethyl and carboxamide aryl substituents showed 33 to 46-fold larger PAM-dependent net-charge responses, indicating selective partitioning of the ligand receptor complexes into the desensitized state.
Collapse
Affiliation(s)
- Marta Quadri
- Department of Chemistry, Biochemistry Division, University of Florida, Gainesville, FL 32611, USA
| | - Roger L Papke
- Department of Pharmacology and Therapeutics, University of Florida, College of Medicine, Gainesville, FL 32610, USA
| | - Nicole A Horenstein
- Department of Chemistry, Biochemistry Division, University of Florida, Gainesville, FL 32611, USA.
| |
Collapse
|
26
|
Lewthwaite AJ, Lambert TD, Rolfe EB, Olgiati S, Quadri M, Simons EJ, Morrison KE, Bonifati V, Nicholl DJ. Novel GCH1 variant in Dopa-responsive dystonia and Parkinson's disease. Parkinsonism Relat Disord 2015; 21:394-7. [PMID: 25634433 PMCID: PMC4379065 DOI: 10.1016/j.parkreldis.2015.01.004] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/22/2014] [Revised: 12/22/2014] [Accepted: 01/06/2015] [Indexed: 11/18/2022]
Abstract
Background GTP cyclohydrolase I (GCH1) mutations are the commonest cause of Dopa-responsive dystonia (DRD). Clinical phenotypes can be broad, even within a single family. Methods We present clinical, genetic and functional imaging data on a British kindred in which affected subjects display phenotypes ranging from DRD to Parkinson's disease (PD). Twelve family members were studied. Clinical examination, dopamine transporter (DAT) imaging, and molecular genetic analysis of GCH1 and the commonest known familial PD-related genes were performed. Results We have identified a novel missense variant, c.5A > G, p.(Glu2Gly), within the GCH1 gene in affected family members displaying a range of phenotypes. Two affected subjects carrying this variant had abnormal DAT imaging. These two with abnormal DAT imaging had a PD phenotype, while the remaining three subjects with the novel GCH1 variant had normal DAT imaging and a DRD phenotype. Conclusions We propose that this GCH1 variant is pathogenic in this family and these findings suggest that similar mechanisms involving abnormal GTP cyclohydolase I may underlie both PD and DRD. GCH1 genetic testing should be considered in patients with PD and a family history of DRD. We have identified a novel missense variant, c.5A > G, p.(Glu2Gly), within the GCH1 gene in family with Dopa responsive dystonia (DRD) and parkinsonism. Those with parkinsonism had abnormal DaTscans, indicating nigrostriatal neurodegeneration. These findings suggest that similar mechanisms involving abnormal GTP cyclohydolase I may underlie both Parkinson's disease and Dopa responsive dystonia.
Collapse
Affiliation(s)
- A J Lewthwaite
- Department of Neurology, Queen Elizabeth Hospital, Birmingham, UK; Department of Neurology, The Dudley Group NHS Foundation Trust, Dudley, UK; School of Clinical and Experimental Medicine, College of Medicine and Dentistry, University of Birmingham, Birmingham, UK
| | - T D Lambert
- Department of Neurology, Queen Elizabeth Hospital, Birmingham, UK
| | - E B Rolfe
- Department of Radiology, Queen Elizabeth Hospital, Birmingham, UK
| | - S Olgiati
- Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands
| | - M Quadri
- Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands
| | - E J Simons
- Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands
| | - K E Morrison
- Department of Neurology, Queen Elizabeth Hospital, Birmingham, UK; School of Clinical and Experimental Medicine, College of Medicine and Dentistry, University of Birmingham, Birmingham, UK
| | - V Bonifati
- Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands
| | - D J Nicholl
- Department of Neurology, Queen Elizabeth Hospital, Birmingham, UK; Department of Radiology, Queen Elizabeth Hospital, Birmingham, UK; Department of Neurology, Sandwell & West Birmingham Hospitals NHS Trust, Birmingham, UK.
| |
Collapse
|
27
|
Matera C, Flammini L, Quadri M, Vivo V, Ballabeni V, Holzgrabe U, Mohr K, De Amici M, Barocelli E, Bertoni S, Dallanoce C. Bis(ammonio)alkane-type agonists of muscarinic acetylcholine receptors: Synthesis, in vitro functional characterization, and in vivo evaluation of their analgesic activity. Eur J Med Chem 2014; 75:222-32. [DOI: 10.1016/j.ejmech.2014.01.032] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2013] [Revised: 01/15/2014] [Accepted: 01/20/2014] [Indexed: 10/25/2022]
|
28
|
Martins S, de Perrot M, Imai Y, Chaparro A, Sakiyama S, Quadri M, Segall L, Waddell T, Liu M, Keshavjee S. Endoscopic delivery of adenoviral-mediated human Interleukin-10 gene to the donor improves post transplant lung function in a large animal model. J Heart Lung Transplant 2002. [DOI: 10.1016/s1053-2498(01)00646-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
29
|
Affiliation(s)
- A Chaballout
- Department of Surgery, King Fahad National Guard Hospital, Riyadh, Kingdom of Saudi Arabia
| | | | | | | | | |
Collapse
|
30
|
Hudgel DW, Devadatta P, Quadri M, Sioson ER, Hamilton H. Mechanism of sleep-induced periodic breathing in convalescing stroke patients and healthy elderly subjects. Chest 1993; 104:1503-10. [PMID: 8222815 DOI: 10.1378/chest.104.5.1503] [Citation(s) in RCA: 28] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
Cerebral vascular ischemic strokes are known to precipitate Cheyne-Stokes periodic breathing. Interestingly, Cheyne-Stokes-like breathing during sleep may be associated with obstructive sleep apnea (OSA) in some individuals. Therefore, it was reasoned that stroke patients with periodic breathing in sleep would be susceptible to OSA. Because oscillations in upper airway resistance can occur as a component of sleep-induced periodic breathing, we hypothesized that stroke patients with sleep-induced periodic breathing would have oscillations in upper airway resistance. These oscillations in resistance would be expected to contribute to OSA. We studied stroke patients with sleep-induced periodic breathing and control subjects to evaluate the relationship between upper airway resistance and ventilation in periodic breathing in sleep. Ventilation and upper airway resistance were measured in presleep wakefulness and in stage 2 NREM sleep. Mean tidal volume, minute ventilation, respiratory cycle timing variables, and upper airway resistance were not different between stroke and control subjects, either awake or asleep. Upper airway resistance increased and ventilation volume decreased from wakefulness to sleep in both groups. In an equivalent number of subjects from each group, reciprocal patterned oscillations in tidal volume and upper airway resistance were present at a 5 to 12.5 breath frequency during sleep. As upper airway resistance increased, tidal volume decreased. Stroke patients had wider fluctuations in upper airway resistance than control subjects, likely contributing to the higher number of sleep-disordered breathing events observed in the stroke patients.
Collapse
Affiliation(s)
- D W Hudgel
- Department of Medicine, Case Western Reserve University, Cleveland
| | | | | | | | | |
Collapse
|